AtheroNova Inc.

AHROQ

US0474383041

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-26.67%

2016	AtheroNova Operations, Inc. Bankruptcy Case Dismissed	CI
2015	First Motion for Exclusivity Period Extension Approved For AtheroNova Operations, Inc.	CI

AtheroNova Inc. Announces Resignation of Chaim Davis from the Board of Directors

December 09, 2014 at 11:02 pm IST

AtheroNova Inc. announced that, effective as of December 3, 2014, Chaim Davis resigned from his position as a member of the board of directors and all committees of board of directors.

Latest news about AtheroNova Inc.

AtheroNova Operations, Inc. Bankruptcy Case Dismissed	18/16/18	CI
First Motion for Exclusivity Period Extension Approved For AtheroNova Operations, Inc.	14/15/14	CI
First Motion for Exclusivity Period Extension Filed by AtheroNova Operations, Inc.	24/15/24	CI
Reorganization Plan and Disclosure Statement Filed by AtheroNova Operations, Inc.	22/15/22	CI
AtheroNova Inc. will Change its Ticker to AHRO.Q from AHRO	04/15/04	CI
AtheroNova To Sell Assets Under Chapter 11	03/15/03	CI
Motion for Joint Administration Approved for AtheroNova Operations, Inc.	03/15/03	CI
AtheroNova Operations, Inc. Filed for Bankruptcy	02/15/02	CI
Motion for Joint Administration Filed by AtheroNova Operations, Inc.	02/15/02	CI
Certain shares of AtheroNova Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 26-JAN-2015.	26/15/26	CI
Certain shares of AtheroNova Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 26-JAN-2015.	26/15/26	CI
AtheroNova Inc. Announces Resignation of Chaim Davis from the Board of Directors	09/14/09	CI
AtheroNova Inc. Announces Resignation of Gary Freeman as a Member of Board of Directors and Chair of Audit Committee	21/14/21	CI
AtheroNova Inc. announced that it has received $0.5 million in funding from W-Net Fund I, L.P.	12/14/12	CI
Atheronova Inc. Accomplishes First Dosing of Subjects for its Phase 1B Clinical Trial with AHRO-001	30/14/30	CI
AtheroNova Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014	19/14/19	CI
Randolph M. Johnson Joins AtheroNova Inc. as Chief Operating Officer	08/14/08	CI
AtheroNova Inc. Auditor Raises 'Going Concern' Doubt	18/14/18	CI
AtheroNova Mulls Acquisitions	18/14/18	CI
AtheroNova Inc. Announces Earnings Results for the Year-Ended December 31, 2013	06/14/06	CI
AtheroNova Inc. Announces Preliminary Positive Phase 1 Clinical Data from Drug AHRO-001	27/14/27	CI
AtheroNova Inc. announced that it has received $1.91 million in funding from Knoll Capital Management.	12/14/12	CI
AtheroNova Inc. announced that it expects to receive $1.40 million in funding from Knoll Capital Management and other investors.	13/14/13	CI
AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001	05/13/05	CI
AtheroNova Inc. Appoints Dr. Erik Stroes to its Clinical Advisory Board	15/13/15	CI

AtheroNova Inc. is a clinical-stage biopharmaceutical company. The Company through its subsidiary, AtheroNova Operations, Inc., is focused on the research and development of compounds to regress atherosclerotic plaque and improve lipid profiles in humans. The Company develops various applications for its compounds to be used for the treatment of atherosclerosis. The Company's development products include AHRO-001 and AHRO-002. The Company's pipeline candidates include applications for the treatment of localized reduction of subcutaneous fat deposits through transdermal application, obesity, hypertension, diabetes and Peripheral Artery Disease (PAD). The Company's lead compound is AHRO-001. Through the process of reverse cholesterol transport, the compound is designed to dissolve plaque within the walls of the arteries and removes it from the body through natural metabolic processes. AHRO-001 and AHRO-002 are orally administered compounds.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATHERONOVA INC.	-26.67%	9.69K
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.17%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research

AtheroNova Inc.

Equities

AHROQ

US0474383041

Biotechnology & Medical Research

AtheroNova Inc. Announces Resignation of Chaim Davis from the Board of Directors

Latest news about AtheroNova Inc.

Chart AtheroNova Inc.

Company Profile

Sector Other Biotechnology & Medical Research